S N Aleksakhina1, M M Kramchaninov2, A D Mikushina1, S E Kubrina1, V V Petkau3, A O Ivantsov1, V M Moiseyenko2, E N Imyanitov1,4,5, A G Iyevleva6,7. 1. Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758. 2. City Cancer Center, Saint-Petersburg, Russia, 197758. 3. Sverdlovskiy Regional Oncological Hospital, Ekatherinburg, Russia, 620036. 4. Saint-Petersburg Pediatric Medical University, Saint-Petersburg, Russia, 194100. 5. I.I. Mechnikov North-Western Medical University, Saint-Petersburg, Russia, 191015. 6. Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia, 197758. aglayai@inbox.ru. 7. Saint-Petersburg Pediatric Medical University, Saint-Petersburg, Russia, 194100. aglayai@inbox.ru.
Abstract
PURPOSE: Endocrine therapy is a mainstay for the treatment of hormone receptor-positive breast cancer (BC); however, only a fraction of patients experience a pronounced response to antagonists of estrogen signaling. There is a need to identify predictors for efficacy of this treatment. METHODS: This study included 138 patients with newly diagnosed metastatic BC, who received upfront endocrine therapy. Archival biopsy specimens were tested for CCND1 and FGFR1 gene amplification and mRNA expression by PCR-based methods. RESULTS: CCND1 and FGFR1 amplification was detected in 24 (17.9%) and 28 (20.9%) of 134 evaluable cases, respectively; 9 carcinomas had concurrent alterations of these two genes. Presence of amplification in at least one locus was more common in tumors of higher grade (p = 0.018) and was associated with higher Ki-67 proliferation index (p = 0.036). CCND1 gene amplification was associated with shorter progression-free survival (PFS) in patients receiving aromatase inhibitors (AI) [16.0 months vs. 32.4 months, HR = 3.16 (95% CI 1.26-7.93), p = 0.014]. FGFR1 status did not significantly affect PFS of AI-treated women; however, objective response to AI was observed less frequently in FGFR1-amplified BC as compared to cases with normal FGFR1 copy number [2/15 (13.3%) vs. 22/46 (47.8%), p = 0.031]. Meanwhile, CCND1/FGFR1 gene status did not influence the outcome of tamoxifen-treated patients. CONCLUSION: Presence of CCND1 and/or FGFR1 amplification is associated with worse outcomes of AI therapy in patients with metastatic BC.
PURPOSE: Endocrine therapy is a mainstay for the treatment of hormone receptor-positive breast cancer (BC); however, only a fraction of patients experience a pronounced response to antagonists of estrogen signaling. There is a need to identify predictors for efficacy of this treatment. METHODS: This study included 138 patients with newly diagnosed metastatic BC, who received upfront endocrine therapy. Archival biopsy specimens were tested for CCND1 and FGFR1 gene amplification and mRNA expression by PCR-based methods. RESULTS:CCND1 and FGFR1 amplification was detected in 24 (17.9%) and 28 (20.9%) of 134 evaluable cases, respectively; 9 carcinomas had concurrent alterations of these two genes. Presence of amplification in at least one locus was more common in tumors of higher grade (p = 0.018) and was associated with higher Ki-67 proliferation index (p = 0.036). CCND1 gene amplification was associated with shorter progression-free survival (PFS) in patients receiving aromatase inhibitors (AI) [16.0 months vs. 32.4 months, HR = 3.16 (95% CI 1.26-7.93), p = 0.014]. FGFR1 status did not significantly affect PFS of AI-treated women; however, objective response to AI was observed less frequently in FGFR1-amplified BC as compared to cases with normal FGFR1 copy number [2/15 (13.3%) vs. 22/46 (47.8%), p = 0.031]. Meanwhile, CCND1/FGFR1 gene status did not influence the outcome of tamoxifen-treated patients. CONCLUSION: Presence of CCND1 and/or FGFR1 amplification is associated with worse outcomes of AI therapy in patients with metastatic BC.
Authors: F S Kenny; R Hui; E A Musgrove; J M Gee; R W Blamey; R I Nicholson; R L Sutherland; J F Robertson Journal: Clin Cancer Res Date: 1999-08 Impact factor: 12.531
Authors: Pankaj G Roy; Norman Pratt; Colin A Purdie; Lee Baker; Alison Ashfield; Phil Quinlan; Alastair M Thompson Journal: Int J Cancer Date: 2010-07-15 Impact factor: 7.396
Authors: Sarah A Jeffreys; Therese M Becker; Sarah Khan; Patsy Soon; Hans Neubauer; Paul de Souza; Branka Powter Journal: Front Endocrinol (Lausanne) Date: 2022-06-17 Impact factor: 6.055